Apellis Pharmaceuticals, Inc. (APLS) Price Target Analysis
Updated Jun 18, 2026
Analyst Rating: Buy
Based on 25 analysts18.6% Above Target
APLS trades 18.6% above Wall Street's consensus target of $33.40.
Current Price$41.03
Average Target$33.40
Target
Current
Low$19.00
Median$35.00
High$48.00
Analyst Target Range
Forward P/E—
PEG Ratio—
Implied Growth—
Analyst Spread86.8%
(Wide Disagreement)
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Consensus Scenario Assumptions
The base valuation assumes APLS achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 25 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
APLS Price Target Analysis
Updated June 23, 2026As of June 23, 2026, Apellis Pharmaceuticals, Inc. (APLS) has a Wall Street consensus price target of $33.40, based on estimates from 25 covering analysts. With the stock currently trading at $41.03, this represents a potential downside of -18.6%. The company has a market capitalization of $5.25B.
Analyst price targets range from a low of $19.00 to a high of $48.00, representing a 87% spread in expectations. The median target of $35.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 18 analysts rating the stock as a Buy or Strong Buy,6 rating it Hold, and 1 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, APLS trades at a trailing P/E of 227.9x.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $3.18, with bear and bull scenarios of $2.00 and $4.18 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside
+732.4%
Industry Consensus
Avg Forward P/E
8.4x
(Value)
Peers with Coverage
10 / 10
Active Analyst Tracking
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 RAREUltragenyx Pharmaceutical Inc. | $2.9B | $29.03 | $48.36 | +76.2% | Buy | — | 33 |
 BEAMBeam Therapeutics Inc. | $3.7B | $35.53 | $48.00 | +40.6% | Buy | — | 27 |
 AKROAkero Therapeutics, Inc. | $4.5B | $54.65 | $48.40 | -11.4% | Buy | — | 14 |
 INVAInnoviva, Inc. | $1.7B | $22.67 | $37.00 | +64.5% | Buy | 6.3x | 10 |
 BCABBioAtla, Inc. | $5M | $3.62 | $250.00 | +6739.9% | Buy | — | 9 |
 REGNRegeneron Pharmaceuticals, Inc. | $63.6B | $612.50 | $836.00 | +37.1% | Buy | 13.1x | 48 |
 BIIBBiogen Inc. | $29.5B | $199.71 | $218.32 | +11.1% | Buy | 13.5x | 48 |
 IONSIonis Pharmaceuticals, Inc. | $12.5B | $75.89 | $109.44 | +47.7% | Buy | — | 32 |
 OMABGrupo Aeroportuario del Centro Norte, S.A.B. de C.V. | $5.3B | $109.67 | $127.00 | +11.4% | Buy | 0.8x | 13 |
 CHRSCoherus Oncology, Inc. | $181M | $1.48 | $6.02 | +306.8% | Buy | — | 16 |
APLS — Frequently Asked Questions
Quick answers to the most common questions about buying APLS stock.
What is the APLS stock price target for 2026?
APLS's consensus price target is $33.4, -18.6% below the current price of $41.03. The 25 analysts tracking APLS see downside risk at present valuations.
Is APLS a buy, sell, or hold?
APLS has a consensus rating of "Buy" based on 25 Wall Street analysts. The rating breakdown is predominantly bullish, with 18 Buy/Strong Buy ratings. The consensus 12-month price target of $33.4 implies -18.6% downside from current levels.
Is APLS stock overvalued or undervalued?
APLS's current price is $41.03 with a consensus target of $33.4 (-18.6% implied move). Analyst estimates suggest the stock is overvalued at current levels.
How high can APLS stock go?
The most bullish Wall Street analyst has a price target of $48 for APLS, while the most conservative target is $19. The consensus of $33.4 represents the median expectation. Our quantitative valuation model projects a bull case target of $4 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover APLS stock?
APLS is heavily covered by Wall Street, with 25 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 17 have Buy ratings, 6 recommend Hold, and 1 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the APLS stock forecast?
The 12-month APLS stock forecast based on 25 Wall Street analysts shows a consensus price target of $33.4, with estimates ranging from $19 (bear case) to $48 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $3, with bear/bull scenarios of $2/$4.
What is APLS's fair value based on fundamentals?
Our quantitative valuation model calculates APLS's fair value at $3 (base case), with a bear case of $2 and bull case of $4. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
Should I buy APLS stock?
Analysts are cautious on APLS, with 1 Sell ratings and a price target of $33.4 (-18.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do APLS price targets vary so much?
APLS analyst price targets range from $19 to $48, a 87% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $33.4 consensus represents the middle ground. Our model's $2-$4 range provides an independent fundamental perspective.
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare